Literature DB >> 12148895

A dual function anti-leukemic agent with anti-thrombotic activity.

Heather Tibbles1, Alexei Vassilev, Fatih M Uckun.   

Abstract

Here we report that treatment with the anti-leukemic compound, LFM-A13 resulted in SYK kinase activation and caused distinct shape changes in platelets. Also provided is electron microscopic evidence that similar shape changes are observed in platelets from XID mice. We propose that LFM-A13 induces a conformational change in the PH domain of BTK and causes BTK to associate with PIP2 which effects actin bundling and shape change.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12148895     DOI: 10.1080/10428190290021650

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  2 in total

1.  Importance of B cell co-stimulation in CD4(+) T cell differentiation: X-linked agammaglobulinaemia, a human model.

Authors:  H Martini; V Enright; M Perro; S Workman; J Birmelin; E Giorda; I Quinti; V Lougaris; M Baronio; K Warnatz; B Grimbacher
Journal:  Clin Exp Immunol       Date:  2011-04-13       Impact factor: 4.330

2.  VEGF controls lung Th2 inflammation via the miR-1-Mpl (myeloproliferative leukemia virus oncogene)-P-selectin axis.

Authors:  Seyedtaghi Takyar; Hema Vasavada; Jian-ge Zhang; Farida Ahangari; Naiqian Niu; Qing Liu; Chun Geun Lee; Lauren Cohn; Jack A Elias
Journal:  J Exp Med       Date:  2013-09-16       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.